stoxline Quote Chart Rank Option Currency Glossary
ADC Therapeutics SA (ADCT)
4.1  0.01 (0.24%)    05-17 16:00
Open: 4.12
High: 4.175
Volume: 410,839
Pre. Close: 4.09
Low: 4
Market Cap: 395(M)
Technical analysis
2024-05-17 4:43:45 PM
Short term     
Mid term     
Targets 6-month :  5.42 1-year :  6.03
Resists First :  4.64 Second :  5.17
Pivot price 4.42
Supports First :  3.79 Second :  3.16
MAs MA(5) :  4.11 MA(20) :  4.47
MA(100) :  3.9 MA(250) :  2.36
MACD MACD :  -0.2 Signal :  -0.1
%K %D K(14,3) :  22.3 D(3) :  20.6
RSI RSI(14): 42.7
52-week High :  6.03 Low :  0.36
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.
[ ADCT ] has closed above bottom band by 20.3%. Bollinger Bands are 17.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 4.18 - 4.21 4.21 - 4.23
Low: 3.95 - 3.98 3.98 - 4
Close: 4.06 - 4.11 4.11 - 4.14
Company Description

ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Headline News

Wed, 15 May 2024
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Singapore News

Wed, 15 May 2024
ADC Therapeutics to Participate in the H.C. Wainwright 2nd - GlobeNewswire

Tue, 14 May 2024
ADC Therapeutics Unveils Strategic Insights in New Presentation - - TipRanks

Tue, 14 May 2024
ADC Therapeutics down 7% following new corporate presentation - Seeking Alpha

Tue, 14 May 2024
ADC Therapeutics SA (ADCT) Reports Q4 Loss, Tops Revenue Estimates - Yahoo News UK

Mon, 13 May 2024
ADC Therapeutics SA (ADCT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Movies UK

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Shares Out 83 (M)
Shares Float 63 (M)
Held by Insiders 20.7 (%)
Held by Institutions 39.4 (%)
Shares Short 858 (K)
Shares Short P.Month 993 (K)
Stock Financials
EPS -2.77
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.35
Profit Margin 0 %
Operating Margin -186.2 %
Return on Assets (ttm) -24.1 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth -5 %
Gross Profit (p.s.) 0
Sales Per Share 0.82
EBITDA (p.s.) -1.79
Qtrly Earnings Growth 0 %
Operating Cash Flow -147 (M)
Levered Free Cash Flow -90 (M)
Stock Valuations
PE Ratio -1.49
PEG Ratio -0.2
Price to Book value -1.75
Price to Sales 4.94
Price to Cash Flow -2.31
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android